The presentation by Robert Dowling, M.D., is scheduled for Monday, November 14 at 11:30 a.m. in the Chapin Theater at the Orange County Convention Center. Overall, there will be four Abiomed-related discussions at this year’s AHA Scientific Sessions.
On the AHA show floor, Abiomed will conduct daily demonstrations at Abiomed booth #2020 and hands-on simulations of the Impella platform.
AHA SCHEDULE OF EVENTS
SATURDAY, NOVEMBER 12
12:15 – 1:45 p.m. Session IV-Best Original Resuscitation Science Poster Session and Luncheon Room W415 (Valencia Ballroom), Posters Orange County Convention Center
•Use of Impella Ventricular Assist Device in Patients with Severe Coronary Artery Disease Presenting with Cardiac Arrest, Venkatakishore Mukku, M.D. MONDAY, NOVEMBER 14
10:45 a.m. – 12:00 p.m. Circulatory Support for High-Risk PCI: When Is This Really Necessary? Room W304bcd Orange County Convention Center Moderator: Srihari Naidu, M.D.
11:30 - 11:40 a.m. Clinical Science: Special Reports II Chapin Theater West Building, Level Three Orange County Convention Center Presentation by Robert Dowling, M.D.
TUESDAY, NOVEMBER 15
11:00 – 11:15 a.m. Percutaneous Circulatory Support in Cardiogenic Shock: Left, Right and Center Room W304bcd Orange County Convention Center
•Clinical Applications and Outcomes of Percutaneous Circulatory Support in Cardiogenic Shock, Eberhard Grube ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
11:30 - 11:40 a.m. Clinical Science: Special Reports II Chapin Theater West Building, Level Three Orange County Convention Center Presentation by Robert Dowling, M.D.
TUESDAY, NOVEMBER 15
11:00 – 11:15 a.m. Percutaneous Circulatory Support in Cardiogenic Shock: Left, Right and Center Room W304bcd Orange County Convention Center
•Clinical Applications and Outcomes of Percutaneous Circulatory Support in Cardiogenic Shock, Eberhard Grube ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Contact:. Abiomed Aimee Maillett, 978-646-1553 Corporate Communications Manager amaillett@abiomed.com.
